Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients

BACKGROUND: Despite impressive efficacy in immunocompetent individuals, the immunogenicity of a single dose of COVID-19 vaccine in B-cell-deplete patients remains unknown. OBJECTIVES: We aimed to quantify real-world vaccine immunogenicity in ocrelizumab recipients. METHODS: We measured post-vaccinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgieva, Zoya G, Dӧffinger, Rainer, Kumararatne, Dinakantha, Coles, Alasdair J, McCarthy, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131405/
https://www.ncbi.nlm.nih.gov/pubmed/34595965
http://dx.doi.org/10.1177/13524585211046786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131405/
https://www.ncbi.nlm.nih.gov/pubmed/34595965
http://dx.doi.org/10.1177/13524585211046786

Ejemplares similares